Compare Denison Mines Corp Ordinary Shares (Canada) (DNN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Denison Mines Corp Ordinary Shares (Canada) vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Denison Mines Corp Ordinary Shares (Canada) trades at $2.45 (market cap $2.14B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.49 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 11.8× Denison Mines Corp Ordinary Shares (Canada)'s market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Denison Mines Corp Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Denison Mines Corp Ordinary Shares (Canada) for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| DNN | RPRX | |
|---|---|---|
Market Cap | $2.14B | $25.27B |
Volume | 56,727,592 | 3,671,183 |
Sector | Energy | Health |
52-Week High | $4.37 | $63.96 |
52-Week Low | $2.27 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.98B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Denison Mines Corp Ordinary Shares (Canada)
Denison Mines is a uranium mining, development, and exploration company focused on Canada's Athabasca Basin. Its portfolio includes the Wheeler River project and interests in other uranium projects and processing facilities.
Read more on DNN →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
